Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

March 31 (Reuters) - Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday. The deal ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

Biogen: recent performance snapshot Biogen (BIIB) has been on investors’ radar after a mixed stretch in the stock, with a slight negative move over the past month but a positive total return over the ...

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Eisai Co. Ltd. and Biogen Inc. on Tuesday said their experimental Alzheimer’s drug significantly slowed cognitive and ...

Biogen acquires Apellis Pharmaceuticals in a deal that brings two marketed complement therapies into its portfolio, ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

Biogen is opening its wallet in a big way, agreeing to buy Apellis Pharmaceuticals in an all-cash deal that values the Waltham biotech at about $5.6 billion. The offer of $41 a share hands Biogen ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...

By Mariam Sunny and Sahil Pandey March 31 (Reuters) - Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding ...